Compare PZZA & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PZZA | NGNE |
|---|---|---|
| Founded | 1984 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.7M | 744.9M |
| IPO Year | 1995 | 2014 |
| Metric | PZZA | NGNE |
|---|---|---|
| Price | $18.40 | $27.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | $28.00 | ★ $77.88 |
| AVG Volume (30 Days) | ★ 1.3M | 328.7K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | ★ 7.34% | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $2,068,421,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $40.64 | ★ N/A |
| Revenue Growth | ★ 14.07 | N/A |
| 52 Week Low | $17.70 | $15.93 |
| 52 Week High | $52.02 | $43.66 |
| Indicator | PZZA | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | 50.19 |
| Support Level | $17.70 | $24.88 |
| Resistance Level | $24.25 | $28.47 |
| Average True Range (ATR) | 0.63 | 2.43 |
| MACD | 0.09 | 0.87 |
| Stochastic Oscillator | 32.75 | 56.16 |
Papa John's International Inc operates and franchises pizza delivery and carryout restaurants and, in certain international markets, dine-in and delivery restaurants. It has four defined reportable segments: Domestic Company-owned restaurants, North America franchising, North America commissaries, and International. The company derives maximum revenue from North America commissaries segment. The North America commissaries segment consists of the operations of its regional dough production and product distribution centers in the United States and Canada and derives its revenues principally from the sale and distribution of food and paper products to Domestic Company-owned and franchised restaurants in the United States and Canada.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.